Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives $30.50 Average PT from Analysts

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) has received a consensus recommendation of “Buy” from the six brokerages that are presently covering the firm, MarketBeat.com reports. Six investment analysts have rated the stock with a buy rating. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $30.50.

Several equities research analysts have recently commented on CPRX shares. StockNews.com raised Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 9th. HC Wainwright reissued a “buy” rating and issued a $30.00 target price on shares of Catalyst Pharmaceuticals in a report on Friday, November 8th. Truist Financial lifted their price target on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a “buy” rating in a research note on Monday, November 11th. Finally, Citigroup increased their price objective on shares of Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the company a “buy” rating in a research note on Friday, August 9th.

Catalyst Pharmaceuticals Trading Down 5.0 %

Shares of CPRX opened at $20.60 on Tuesday. Catalyst Pharmaceuticals has a twelve month low of $13.00 and a twelve month high of $24.27. The firm has a market capitalization of $2.46 billion, a P/E ratio of 17.46, a PEG ratio of 3.51 and a beta of 0.75. The firm’s 50-day moving average is $20.99 and its two-hundred day moving average is $18.34.

Insider Activity at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Steve Miller sold 150,000 shares of the stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $20.35, for a total transaction of $3,052,500.00. Following the transaction, the insider now owns 675,124 shares of the company’s stock, valued at $13,738,773.40. This represents a 18.18 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, Director David S. Tierney sold 15,000 shares of the firm’s stock in a transaction on Wednesday, August 21st. The stock was sold at an average price of $20.10, for a total value of $301,500.00. Following the sale, the director now owns 348,874 shares in the company, valued at $7,012,367.40. This trade represents a 4.12 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 11.00% of the company’s stock.

Institutional Trading of Catalyst Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CPRX. Vestcor Inc boosted its holdings in shares of Catalyst Pharmaceuticals by 18.4% in the 3rd quarter. Vestcor Inc now owns 60,431 shares of the biopharmaceutical company’s stock valued at $1,201,000 after purchasing an additional 9,379 shares during the last quarter. Barclays PLC boosted its holdings in Catalyst Pharmaceuticals by 129.4% in the third quarter. Barclays PLC now owns 248,458 shares of the biopharmaceutical company’s stock valued at $4,939,000 after acquiring an additional 140,129 shares during the last quarter. XTX Topco Ltd boosted its holdings in Catalyst Pharmaceuticals by 73.3% in the third quarter. XTX Topco Ltd now owns 19,294 shares of the biopharmaceutical company’s stock valued at $384,000 after acquiring an additional 8,160 shares during the last quarter. iSAM Funds UK Ltd purchased a new stake in Catalyst Pharmaceuticals during the third quarter valued at about $216,000. Finally, Jane Street Group LLC increased its stake in Catalyst Pharmaceuticals by 245.4% during the third quarter. Jane Street Group LLC now owns 401,908 shares of the biopharmaceutical company’s stock worth $7,990,000 after acquiring an additional 285,564 shares during the last quarter. Hedge funds and other institutional investors own 79.22% of the company’s stock.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.